Cochrane · systematic review · CD012095
Celecoxib for rheumatoid arthritis
Fidahic, M, Jelicic Kadic, A, Radic, M, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 7.1%Very low 0 · 0%Low 7 · 50%Moderate 6 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Celecoxib versus placebo
Population: people with rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical improvement: American College of Rheumatology 20% improvement criteria (ACR20) Celecoxib vs placebo | RR 1.53 [1.25, 1.86] | 2 studies · 873 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Pain: self‐reported visual analogue scale (VAS) from 0 to 100 points (where 0 is no pain) Celecoxib vs placebo | no estimate extracted | 1 study · 706 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Physical function: Health Assessment Questionnaire Disability Index (HAQ) scale 0 to 3; higher scores means worse functional ability; Celecoxib vs placebo | no estimate extracted | 1 study · 706 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Cardiovascular events (myocardial infarction, stroke) Celecoxib vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Incidence of gastroduodenal ulcers ≥ 3 mm Celecoxib vs placebo | Peto OR 1.26 [0.44, 3.63] | 1 study · 392 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Short‐term serious adverse events Celecoxib vs placebo | Peto OR 0.87 [0.28, 2.69] | 1 study · 706 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Total withdrawals; Celecoxib vs placebo | RR 0.61 [0.52, 0.72] | 1 study · 706 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Celecoxib versus traditional NSAIDs
Population: people with rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical improvement: American College of Rheumatology 20% improvement criteria (ACR20) Celecoxib vs traditional NSAIDs | RR 1.1 [0.99, 1.23] | 4 studies · 1981 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Pain: self‐reported visual analogue scale (VAS) from 0 to 100 (where 0 is no pain) Celecoxib vs traditional NSAIDs | no estimate extracted | 3 studies · 1504 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Physical function: Health Assessment Questionnaire Disability Index (HAQ) scale 0 to 3; higher scores means worse functional ability; Celecoxib vs traditional NSAIDs | no estimate extracted | 2 studies · 849 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Cardiovascular events (myocardial infarction, stroke) Celecoxib vs traditional NSAIDs | Peto OR 1.13 [0.07, 18.33] | 1 study · 149 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Incidence of gastroduodenal ulcers ≥ 3 mm Celecoxib vs traditional NSAIDs | RR 0.21 [0.14, 0.32] | 5 studies · 1568 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Short‐term serious adverse events Celecoxib vs traditional NSAIDs | Peto OR 0.71 [0.39, 1.28] | 5 studies · 2154 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Total withdrawals; Celecoxib vs traditional NSAIDs | RR 0.73 [0.62, 0.86] | 6 studies · 2639 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |